Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Appointed director
Notes underwriting agrmnt
Kura Oncology, Inc. (KURA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Kura Oncology Reports Second Quarter 2023 Financial Results – Enrollment in registration-directed trial of ziftomenib in NPM1-mutant AML continues to outperform projections – – First patients dosed in combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – Late-breaking clinical data for ziftomenib in NPM1-mutant AML presented at EHA – – Continued evidence of clinical activity observed in trial of tipifarnib plus alpelisib in PIK3CA-dependent HNSCC – – First-in-human study of next-generation FTI KO-2806 to begin in second half of 2023 – – $477 million in cash, equivalents and investments provide runway to mid-2026 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, Aug. 3, 2023– Kura Oncology, Inc. , a clinical-stage biopharmaceutical c..."
06/12/2023 8-K Investor presentation
Docs: "Presentation Materials of Kura Oncology, Inc"
06/02/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/02/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "KURA ONCOLOGY, INC. OPTION AGREEMENT Pursuant to your Stock Option Grant Notice and this Option Agreement, Kura Oncology, Inc. has granted you an option under its Amended and Restated 2014 Equity Incentive Plan to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice . If there is any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan. The details of your option, in addition to those set forth in the Gr..."
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/20/2023 ARS Form ARS - Annual Report to Security Holders:
04/19/2023 8-K Quarterly results
04/06/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
02/23/2023 10-K Annual Report for the period ended December 31, 2022
02/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results – Phase 1 data for ziftomenib highlighted by 30% CR rate among 20 patients with NPM1-mutant AML treated at recommended Phase 2 dose – – Multiple patients dosed in registration-directed trial of ziftomenib in NPM1-mutant AML – – First combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML on track to initiate in first half of 2023 – – IND for KO-2806, a next-generation farnesyl transferase inhibitor, cleared by FDA – – $25 million strategic equity investment from Bristol Myers Squibb – – $438 million in cash, equivalents and investments provide runway into fourth quarter of 2025 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, Feb. 23, 2023 – Kura Oncology, Inc. , ..."
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A EcoR1 Capital, LLC reports a 9.9% stake in Kura Oncology, Inc.
02/10/2023 SC 13G/A Flynn James E reports a 3.6% stake in Kura Oncology, Inc.
02/03/2023 SC 13G/A STATE STREET CORP reports a 6.6% stake in AMENDED FILING KURA ONCOLOGY INC
01/31/2023 SC 13G/A BlackRock Inc. reports a 7.6% stake in Kura Oncology Inc
01/13/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
01/09/2023 8-K Investor presentation
Docs: "Presentation Materials of Kura Oncology, Inc",
"Presentation Materials of Kura Oncology, Inc"
12/12/2022 8-K Quarterly results
12/05/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
11/03/2022 8-K Quarterly results
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
11/03/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
09/29/2022 8-K Quarterly results
08/03/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/03/2022 8-K Quarterly results
Docs: "Kura Oncology Reports Second Quarter 2022 Financial Results – Recommended Phase 2 dose for ziftomenib identified, pending FDA review – – Additional 18 patients enrolled in KOMET-001 trial of ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – Preliminary activity observed in KURRENT-HN trial of tipifarnib plus alpelisib in PIK3CA-dependent HNSCC, first patient dosed in HRAS overexpression cohort – – $450 million in cash, cash equivalents and investments provide runway through 2024 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, August 3, 2022 – Kura Oncology, Inc. , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported second quarter 2022 financial results and..."
06/23/2022 8-K Quarterly results
05/04/2022 10-Q Quarterly Report for the period ended March 31, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy